India May Go For Reference Pricing As Negotiated Pricing May Endanger Compulsory License Policy
This article was originally published in PharmAsia News
Reference pricing leaves room for scaling down prices via compulsory licenses.
You may also be interested in...
With Over 348 Drugs In Proposed Pricing Policy, India Aims To Balance Industry Growth With Affordable Drugs
MUMBAI - After lying in hibernation for several years, policy proposals for tighter government control on pricing of the most used medicines in India is back in the headlines as the Department of Pharmaceuticals last week posted a comprehensive draft pricing policy and called for feedback from stakeholders before Nov. 30
PERTH, Australia - Australia has the lowest prices for new medicines among developed countries, according to a UK Department of Health report on the Pharmaceutical Price Regulation Scheme
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.